BSE filing, NSE: WELCURE. Summary written from the filing by ALFA Finder's alert engine.
Welcure Drugs & Pharmaceuticals Ltd: key numbers
- Share price
- ₹0.18
- Market cap
- ₹22.25 Cr
- Revenue (annual)
- ₹365.5 Cr
- Net profit (annual)
- ₹-5.49 Cr
- P/E (TTM)
- -1.3×Sector 45.9×
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Welcure Drugs & Pharmaceuticals Ltd
All →Welcure Drugs & Pharmaceuticals Other Announcement
Welcure Drugs submitted its Annual Secretarial Compliance Report for FY2026 under Regulation 24A. The report confirms overall compliance while noting historical fines paid for earlier procedural delays.
Welcure Drugs & Pharmaceuticals Q4 FY26 Results: Net Loss of ₹49.9 Cr
Welcure Drugs & Pharmaceuticals Ltd reported a net loss of ₹49.9 Cr for Q4 FY26.
- Key figure
- Net loss ₹49.9 Cr
Welcure Drugs & Pharmaceuticals Financial Results
Welcure Drugs and Pharmaceuticals reported annual total income of ₹367.00 Crore for FY26. The Board approved audited results, showing a net annual loss of ₹5.49 Crore.
- Value
- ₹367.0 Cr
Welcure Drugs & Pharmaceuticals Board Meeting Date
Welcure Drugs scheduled a board meeting for May 29, 2026. Directors will consider and approve audited financial results for the 2026 fiscal year.
Welcure Drugs & Pharmaceuticals Debt & Borrowing
Welcure Drugs & Pharmaceuticals Ltd confirmed it does not meet SEBI's 'Large Corporate' criteria for the financial year ended March 31, 2026. Consequently, the company is exempt from mandatory incremental borrowing through debt securities. Its outstanding borrowings as of the reporting date were nil.
Welcure Drugs & Pharmaceuticals Other Announcement
Welcure Drugs & Pharmaceuticals Ltd submitted its Regulation 74(5) certificate for the quarter and year ended March 31, 2026. The registrar, Skyline Financial Services, confirmed that no physical share certificates were received for dematerialization during this period. This is a routine regulatory disclosure with no impact on business operations.
Other board meeting outcome announcements
All →Emergent Industrial Solutions Board Meeting Outcome
Emergent Industrial Solutions reconstituted its four board committees, reassigning existing directors across Audit, Nomination, Stakeholders Relationship, and CSR roles. This is routine governance with no financial impact.
Winsol Engineers Board Meeting Outcome
Winsol Engineers' board approved AoA changes to allow voluntary dividend waiver and postal ballot logistics. All decisions are routine governance matters with no material business impact.
Nirlon Board Meeting Outcome
Nirlon Ltd's board approved a modification to its Dividend Distribution Policy on November 2, 2026. This is a routine governance update with no dividend declared or cash impact.
Novus Loyalty Board Meeting Outcome
Novus Loyalty's board approved voluntary quarterly financial reporting from the December 2026 quarter, enhancing transparency beyond the mandatory half-yearly SME disclosure requirement.
Bharat Global Developers Board Meeting Outcome
Board approved shifting registered office within Ahmedabad and postponed Q1 and H1 FY27 financial results to a subsequent meeting. No material business decision was taken.
Pasari Spinning Mills Board Meeting Outcome
Pasari Spinning Mills reconstituted its Audit, NRC and SRC committees after an independent director resigned and Ms. Bhavna Agrawal was appointed. The change takes effect from the 30 October 2026 board meeting.